The Pancreatic Unit, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Pancreatology. 2013 Sep-Oct;13(5):534-8. doi: 10.1016/j.pan.2013.07.283. Epub 2013 Jul 31.
The pre-operative neutrophil-to-lymphocyte ratio (NLR), when ≥5 has been associated with reduced survival for patients with various gastrointestinal tract cancers, however, it's prognostic value in patients with periampullary tumour has not been reported to date.
To determine the prognostic value of pre-operative NLR in terms of survival and recurrence of resected periampullary carcinomas.
This was a retrospective cohort study of consecutive patients undergoing pancreatoduodenectomy (PD) for periampullary carcinoma (pancreatic, ampullary, cholangiocarcinoma) identified from a departmental database. The effect of NLR upon survival and recurrence was explored.
Overall median survival amongst 228 patients was 24 months (inter-quartile range [IQR]: 12-43). The median survival for those whose NLR was <5 was not significantly greater than those patients whose NLR was ≥5 (24 months [IQR: 14-42] versus 13 months [IQR: 8-48], respectively; p = 0.234). However, for those that developed recurrence, survival was greater in those with an NLR <5 at (20 months [IQR: 12-27] versus 11 months [IQR: 7-22], respectively; p = 0.038). This effect was most marked in those patients with cholangiocarcinoma (p = 0.019) whilst a trend to worse survival was seen in those with pancreatic adenocarcinoma. No effect was seen in patients with ampullary carcinoma (p = 0.516).
This study provides further evidence that pre-operative NLR offers important prognostic information regarding disease-free survival. This effect, however, is dependent upon the tumour type amongst patients undergoing PD.
术前中性粒细胞与淋巴细胞比值(NLR)≥5 与多种胃肠道癌症患者的生存率降低相关,然而,目前尚未报道其在胰胆管交界部肿瘤患者中的预后价值。
确定术前 NLR 在胰胆管交界部癌患者的生存和复发方面的预后价值。
这是一项回顾性队列研究,纳入了从科室数据库中确定的连续接受胰十二指肠切除术(PD)治疗胰胆管交界部癌(胰腺癌、壶腹癌、胆管癌)的患者。探讨 NLR 对生存和复发的影响。
228 例患者的总体中位生存时间为 24 个月(四分位距 [IQR]:12-43)。NLR<5 的患者的中位生存时间与 NLR≥5 的患者无显著差异(24 个月 [IQR:14-42]与 13 个月 [IQR:8-48],分别;p=0.234)。然而,对于那些发生复发的患者,NLR<5 的患者的生存时间更长(20 个月 [IQR:12-27]与 11 个月 [IQR:7-22],分别;p=0.038)。这种影响在胆管癌患者中最为明显(p=0.019),而在胰腺癌患者中则存在生存时间较差的趋势。在壶腹癌患者中未见明显影响(p=0.516)。
本研究进一步提供了证据表明术前 NLR 提供了有关无病生存的重要预后信息。然而,这种影响取决于 PD 治疗患者的肿瘤类型。